Dynamic Contrast-enhanced Magnetic Resonance Imaging for Patients with Breast Cancer Receiving First-line Bevacizumab and Paclitaxel

Bevacizumab plus paclitaxel shows promise for metastatic disease; however, there is no predictive biomarker. Dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) is widely used to evaluate the efficacy of anti-angiogenic therapies. Patients with locally advanced/metastatic breast cancer...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2018-09, Vol.38 (9), p.5459-5463
Main Authors: Nakatsukasa, Katsuhiko, Ouchi, Yoshimi, Sakaguchi, Kouichi, Goto, Mari, Konishi, Eiichi, Taguchi, Tetsuya
Format: Article
Language:English
Subjects:
Angiogenesis
Bevacizumab
Biomarkers
Breast cancer
Cancer
Chemotherapy
Immunotherapy
Magnetic permeability
Magnetic resonance imaging
Medical imaging
Metastases
Metastasis
Monoclonal antibodies
NMR
Nuclear magnetic resonance
Paclitaxel
Patients
Permeability
Regression
Resonance
Targeted cancer therapy
Tumors
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Bevacizumab plus paclitaxel shows promise for metastatic disease; however, there is no predictive biomarker. Dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) is widely used to evaluate the efficacy of anti-angiogenic therapies. Patients with locally advanced/metastatic breast cancer who had not received any prior chemotherapy or hormone therapy were included. DCE-MRI was conducted at baseline and after one and two cycles of bevacizumab and paclitaxel. The percentage change in the volume transfer constant (ΔKtrans) and the correlation of ΔKtrans with tumour regression and time to progression (TTP) were evaluated. The mean ΔKtrans from baseline after one and two cycles was -51.4% and -55.1%, respectively. Patients with ΔKtrans ≥50% displayed more tumour regression than those with ΔKtrans
ISSN:0250-7005
1791-7530
DOI:10.21873/anticanres.12878